BioDelivery Sciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

BioDelivery Sciences' presentation is scheduled for Tuesday, November
17, at 4:10 PM Eastern Time.

Dr. Sirgo will be providing an update on the October 2009 commercial
launch of ONSOLIS (fentanyl buccal soluble film) as well as an update on
BDSI's product pipeline, which includes BEMA Buprenorphine and two
additional BEMA-formulated product candidates recently added to the
portfolio. Dr. Sirgo will also discuss anticipated Company milestones
for the remainder of 2009 and those expected to occur in 2010.

The presentation will be webcast live and can be accessed at www.biodeliverysciences.com.
For those who are not available to listen to the live broadcast, the
presentation will be archived.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI | Quote | Chart | News | PowerRating) is a specialty pharmaceutical
company that is leveraging its novel and proprietary patented drug
delivery technologies to develop and commercialize, either on its own or
in partnerships with third parties, new applications of proven
therapeutics. BDSI is focusing on developing products to meet unmet
needs in the areas of pain management and oncology supportive care.
BDSI's pain franchise currently consists of two products utilizing the
Company's patented BEMA buccal soluble film technology: ONSOLIS
(fentanyl buccal soluble film) which was approved by FDA on July 16,
2009, for the management of breakthrough pain in patients with cancer,
eighteen years of age and older, who are already receiving and who are
tolerant to opioid therapy for their underlying persistent cancer pain,
and BEMA Buprenorphine, an analgesic in Phase 2 clinical development
with at least one potential target indication for the treatment of
moderate to severe pain. Additional product candidates are being
developed utilizing the BEMA technology for conditions such as
nausea/vomiting and migraine. The Company is also working with its
patented Bioral cochleate technology to facilitate oral dosing of drugs
otherwise given by intravenous administration. The first product under
development using the technology is Bioral Amphotericin B. The Company's
headquarters is located in Raleigh, North Carolina. For more information
please visit www.biodeliverysciences.com.

BDSI(R), BEMA(R) and Bioral(R) are registered
trademarks, and ONSOLIS(TM) is a trademark of BioDelivery
Sciences International, Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of
BioDelivery Sciences International, Inc. (the "Company") related thereto
contain, or may contain, among other things, certain "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve significant
risks and uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans, objectives,
projections, expectations and intentions and other statements identified
by words such as "projects," "may," "could," "would," "should,"
"believes," "expects," "anticipates," "estimates," "intends," "plans,"
or similar expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are subject to
significant risks and uncertainties, including those detailed in the
Company's filings with the Securities and Exchange Commission. Actual
results may differ significantly from those set forth in the
forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control).

SOURCE: BioDelivery Sciences International, Inc.

ICR, Inc. 
Donald Ellis 
925-253-1240 
donald.ellis@icrinc.com 
or 
BioDelivery Sciences International, Inc. 
Al Medwar 
VP, Marketing and Corporate Development 
919-582-9050 
amedwar@bdsinternational.com

For full details on Biodelivery Sciences Intl Inc (BDSI) BDSI. Biodelivery Sciences Intl Inc (BDSI) has Short Term PowerRatings at TradingMarkets. Details on Biodelivery Sciences Intl Inc (BDSI) Short Term PowerRatings is available at This Link.